Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Status:
Terminated
Trial end date:
2020-05-28
Target enrollment:
Participant gender:
Summary
This is an open-label, non-randomized two arm Phase 2 study of intravenous nivolumab plus
intravenous ipilimumab or intravenous relatlimab in patients with metastatic melanoma
stratified by MHC-II expression.